Summit Therapeutics
SMMT
61 hedge funds and large institutions have $34.6M invested in Summit Therapeutics in 2022 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 18 increasing their positions, 7 reducing their positions, and 9 closing their positions.
810% more capital invested
Capital invested by funds: $3.8M → $34.6M (+$30.8M)
178% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 9
157% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 7
36% more funds holding
Funds holding: 45 → 61 (+16)
21% more call options, than puts
Call options by funds: $5.59M | Put options by funds: $4.63M
2.44% more ownership
Funds ownership: 1.59% → 4.03% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$3.64M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.21M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$877K |
| 4 |
SPIA
Steward Partners Investment Advisory
New York
|
+$555K |
| 5 |
AIC
AWM Investment Company
New York
|
+$546K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$514K |
| 2 |
Morgan Stanley
New York
|
-$241K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$85.2K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$39.5K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$35K |
SMMT Hedge Fund Activity: Q4 2022 in Review
61 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q4 2022, worth a combined $34.6M — up 810% from $3.8M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new SMMT positions and 9 closed out — a net gain of 16 holders — while 18 added to existing stakes and 7 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $3.64M. The largest seller was Millennium Management, exiting entirely with an estimated $514K sold.
- 61 institutional investors held Summit Therapeutics (SMMT) as of Q4 2022, up from 45 in Q3 2022.
- Funds reported $34.6M of Summit Therapeutics stock for Q4 2022, up 810% quarter-over-quarter.
- 25 funds opened new Summit Therapeutics positions in Q4 2022 and 9 closed out, a net change of +16 holders.
- The largest Summit Therapeutics buyer in Q4 2022 was Baker Bros. Advisors, an estimated $3.64M added.
- The largest Summit Therapeutics seller in Q4 2022 was Millennium Management, an estimated $514K sold.
Based on aggregated 13F filings for Q4 2022.